Technical Articles
16 May 2024
Characterization and Evaluation of Amorphous Solid Dispersion-Part 2
16 May 2024
en
Contrary to popular belief, early formulation development is not simply dumping API in a vehicle and gavage feeding an animal. If you do this, you will most likely lose time and money with unnecessary and confusing PK studies. This led to the development of our SMART biopharmaceutical solutions that offer input from our scientific advisory board: A one-stop shop from candidate selection through GMP FIH.
This is an integrated approach to finding the right form and formulation at every step of the development cycle using decision trees and guidance documents built from our over 80 years of innovative pharmaceutical experience. Using our SMART services will lead to the shortest possible development timelines with limited resource utilization.
Our formulation approaches to deliver molecules to support PK/Efficacy/Tox Studies include solution and suspension formulation selection through vehicle screening, solubilization through pH adjustment, co-solvents, surfactants, cyclodextrin, in-situ salt formation. In addition, we also apply special drug delivery technologies for insoluble compounds.
■ Conventional - Solution/Suspension Formulations
● pH Adjustment
● Co-solvents
● Surfactants
● Cyclodextrin
● In-situ Salt
■ Enabling - Enhance Solubility & Bioavailability
● Amorphous Solid Dispersion
- Spray drying or Lyophilization
● Size Reduction
- Nano-milling: Nano-suspension
- Micronization by Jet-milling
● Lipid-based Formulation
● Self-emulsifying Drug Delivery Systems (SEDDS)
|  |  |  |  |
| Micronization 1~10 μm | Nano-milling <1000 nm | Spray Drying ASD | Freeze Drying Lyophilization | Extruder Liposome |
